Evidence map›Paper›PMID 36941584›Full record

ArticleMolecular cancer2023

Retraction Note: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.

Zhuo-Yuan Lin, Guo Chen, Yan-Qiong Zhang, Hui-Chan He, Yu-Xiang Liang, Jian-Heng Ye, Ying-Ke Liang, Ru-Jun Mo, Jian-Ming Lu, Yang-Jia Zhuo and 6 more

RetractedOpen access · goldFull text readRetraction Notice
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Zhuo-Yuan Lin *Department of Urology, Guangdong Key Laboratory of Clinical Molecular, Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou, Medical University, Guangzhou, 510180, China.
Guo Chen *Department of Urology, Guangdong Key Laboratory of Clinical Molecular, Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou, Medical University, Guangzhou, 510180, China.
Yan-Qiong Zhang *Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Hui-Chan He *Department of Urology, Guangdong Key Laboratory of Clinical Molecular, Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou, Medical University, Guangzhou, 510180, China.
Yu-Xiang LiangDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular, Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou, Medical University, Guangzhou, 510180, China.
Jian-Heng YeDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular, Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou, Medical University, Guangzhou, 510180, China.
Ying-Ke LiangDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular, Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou, Medical University, Guangzhou, 510180, China.
Ru-Jun MoDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular, Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou, Medical University, Guangzhou, 510180, China.
Jian-Ming LuDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular, Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou, Medical University, Guangzhou, 510180, China.
Yang-Jia ZhuoDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular, Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou, Medical University, Guangzhou, 510180, China.
Yu ZhengDepartment of Urology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Medical University, Guangzhou, 510260, China.
Fu-Neng JiangDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular, Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou, Medical University, Guangzhou, 510180, China.
Zhao-Dong HanDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular, Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou, Medical University, Guangzhou, 510180, China.
Shu-Lin WuDepartment of Pathology, Massachusetts General Hospital and Harvard, Medical School, Boston, MA, 02114, USA.
Wei-de ZhongDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular, Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou, Medical University, Guangzhou, 510180, China. zhongwd2009@live.cn.
Chin-Lee WuDepartment of Urology, Guangdong Key Laboratory of Clinical Molecular, Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou, Medical University, Guangzhou, 510180, China. cwu2@mgh.harvard.edu.
First Affiliated Hospital of Guangzhou Medical University · CNHarvard University · USSecond Affiliated Hospital of Guangzhou Medical University · CNJinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36941584
PMCPMC10026411
OpenAlexW4328048950

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read4
identifiers read1
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.